If you or a loved one are being treated for advanced Parkinson’s disease, consider ND0612 clinical studies.
BeyoND (NCT02726386) is an ongoing multi-center, international, open-label, long-term safety study of ND0612 for the management of motor fluctuations in Parkinson’s disease (PD). Adult patients with a diagnosis of PD on LD treatment were eligible for the study if they had more than 2 hours of ‘off-time’ a day. Patients were assigned to open-label treatment with ND0612 for either 24 hours or 16 hours for a total LD/CD daily dose of 720/90mg. Adjunct oral PD medications could be taken as needed. Safety and tolerability were assessed through adverse events and percentage of early treatment discontinuations. At the end of the study, patients can opt to continue their allocated treatment for an additional 5-years.
The BeyoND study recruitment has been completed, the study is continuing.
BouNDless (NCT04006210) is a phase III randomized, active-controlled trial designed to assess the efficacy and safety of treatment with continuous subcutaneous ND0612 in comparison to oral immediate-release LD/CD in patients with PD experiencing motor fluctuations.
The BouNDless study is now recruiting!